News | Cardiovascular Ultrasound | June 13, 2016

Calculating Aortic Flow Rate Superior Test for Patient Risk Stratification

Mayo Clinic study finds echocardiography suitable test to evaluate heart function via dobutamine response

ASE 2016, Mayo Clinic study, echocardiography, aortic flow rate, patient risk stratification

June 13, 2016 — Researchers from Mayo Clinic believe they have found a better way to risk stratify some of their most fragile patients.

Patients with reduced left ventricular ejection fraction (LFLGAS) being evaluated with dobutamine, a medically induced “stressor,” to view their heart function at work need special care. Looking at a cohort of these patients, the researchers found that using echocardiography to measure their aortic flow rate was a good predictor for their risk. “Our work highlights, for the first time, the importance of calculating aortic valve flow rate to risk stratify patients undergoing dobutamine stress echo for a low-flow, low-gradient aortic stenosis. We showed that flow rate goes above and beyond contractile reserve, which is what is being used right now, to risk stratify these patients,” said Said Alsidawi, M.D.

Researchers on the study, Low-flow, Low-gradient Aortic Stenosis: Prognostic Value of Flow Rates vs. Stroke Volume During Dobutamine Echocardiography, included Alsidawi, Robert B. McCully, Christopher G. Scott, Sorin V. Pislaru, Patricia A. Pellikka, Mackram F. Eleid, Jae K. Oh, and Vuyisile T. Nkomo from the Division of Cardiovascular Diseases, Mayo Clinic School of Medicine, Rochester, Minn.

This finding could be useful for many clinicians as patients presenting with low ejection fractions (EF) could be exhibiting an early sign of heart failure. These clinicians need good diagnostic options to assess whether valve replacement surgery or other therapies are needed.

Alsidawi presented a poster based on this research during the American Society of Echocardiography 27th Annual Scientific Sessions, June 10-14 in Seattle. This research was submitted as part of the “Valvular Heart Disease” topic area.

For more information: www.asescientificsessions.org


Related Content

News | ASE

June 12, 2024 — Royal Philips has announced its next-generation AI-enabled cardiovascular ultrasound platform to help ...

Home June 12, 2024
Home
Feature | ASE | Christine Book

June 4, 2024 — The countdown has begun ahead of the American Society of Echocardiography 35th Annual ASE Scientific ...

Home June 04, 2024
Home
News | ASE

July 5, 2023 — Research presented during the American Society of Echocardiography’s 34th Annual Scientific Sessions, ASE ...

Home July 05, 2023
Home
News | ASE

June 29, 2023 — At the conclusion of the American Society of Echocardiography 2023 Scientific Sessions, ASE 2023, the ...

Home June 29, 2023
Home
News | ASE

June 29, 2023 — A large, multi-center study presented during the American Society of Echocardiography’s (ASE) 34th ...

Home June 29, 2023
Home
Feature | ASE | Christine Book

June 27, 2023 — The 2023 American Society of Echocardiography Scientific Sessions, ASE 2023, “Foundations and the future ...

Home June 27, 2023
Home
News | ASE

June 23, 2023 — Building on its established leadership in cardiovascular ultrasound, Philips will showcase its ...

Home June 23, 2023
Home
News | ASE

June 13, 2023 — Core Sound Imaging, Inc. has announced the introduction of the Studycast Integration Program. The ...

Home June 13, 2023
Home
News | ASE
May 5, 2022 – The American Society of Echocardiography (ASE), the largest global organization for cardiovascular ...
Home May 05, 2022
Home
News | ASE
April 21, 2022 – The American Society of Echocardiography (ASE) is pleased to announce that its membership has elected ...
Home April 21, 2022
Home
Subscribe Now